Clinical Trials Logo

Solid Neoplasms clinical trials

View clinical trials related to Solid Neoplasms.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04420884 Recruiting - Solid Neoplasms Clinical Trials

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

iintune-1
Start date: July 22, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. In the dose escalation phase, escalating doses of dazostinag are being tested alone and in combination with pembrolizumab to treat participants who have advanced or metastatic solid tumors. In the dose expansion phase, dazostinag will be studied with pembrolizumab with or without chemotherapy in participants with untreated metastatic or recurrent, unresectable squamous cell carcinoma of head and neck (SCCHN) and in combination with pembrolizumab in third-line or later recurrent locally advanced or metastatic microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and third-line recurrent locally advanced or metastatic microsatellite stable/mismatch repair proficient (MSS/pMMR) colorectal cancer (CRC).

NCT ID: NCT04407676 Recruiting - Solid Neoplasms Clinical Trials

Improving Informed Consent for Early Phase Anti-Cancer Trials

CONSENT
Start date: June 26, 2020
Phase: N/A
Study type: Interventional

The purpose of the trial will be to test whether providing both a short summary PIS and a link to a set of online video modules will improve patient understanding (those considering early phase clinical trials) as measured on the Quality of Informed Consent questionnaire (Part A), as compared to a control group who are provided only the normal PIS, and also to assess user acceptability and feasibility of these interventions.